Modeling interleukin-2-based immunotherapy in AIDS pathogenesis

Autor(es)

Joly, Marcel ^{[1, 2]} ; Odloak, Darci ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Proc Control & Simulat Lab, BR-05508900 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Publ Hlth, BR-01246904 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Theoretical Biology; v. 335, p. 57-78, OCT 21 2013.
• Citações Web of Science: 6

Resumo

In this paper, we sought to identify the CD4(+) T-cell dynamics in the course of HIV infection in response to continuous and intermittent intravenous courses of interleukin-2 (IL-2), the principal cytokine responsible for progression of CD4(+) T-lymphocytes from the Cl to the S phase of the cell cycle. Based on multivariate regression models, previous literature has concluded that the increase in survival of CD4(+) T-cell appears to be the critical mechanism leading to sustained CD4(+) T-cell levels in HIV-infected patients receiving intermittent IL-2 therapy. Underscored by comprehensive mathematical modeling, a major finding of the present work is related to the fact that, rather than due to any increase in survival of CD4(+) T-cells, the expressive, selective and sustained CD4(+) T-cell expansions following IL-2 administration may be related to the role of IL-2 in modulating the dynamics of Fas-dependent apoptotic pathways, such as activation-induced cell death (AICD) or HIV-specific apoptotic routes triggered by viral proteins. (C) 2013 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 99/09897-4 - Metodologias para a operação de Scheduling ótimos de sistemas reativos em batelada
• Beneficiário: Marcel Joly
• Linha de fomento: Bolsas no Brasil - Doutorado